Hmmmm...Perhaps it's some institutional buying, as they are targeting high 30's to low 40's for s/p!(Fosters, ubs, etc.)With some 400% gain potential, could make their books look a little better than past results, imo.Cheers :)
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
